Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
IVR-C Invesco Mortgage Capital Inc
MSM MSC Industrial Direct Co Inc
BLUE bluebird bio Inc
ENSV Enservco Corp
ULIHF United Laboratories International Holdings Ltd
ABOIF Aboitiz Equity Ventures Inc
VYNE Vyne Therapeutics Inc
CEAD CEA Industries Inc
BFRI Biofrontera Inc
Go

Health Care : Biotechnology | Small Cap Value

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.

Price: Delayed
$133.81

Day's Change: 7.71 (6.11%)

Bid: --

Ask: --

B/A Size: --

Day's High: 134.00

Day's Low: 123.70

Volume (Below Average) Today's volume of 350,060 shares is on pace to be lower than KRTX's 10-day average volume of 433,407 shares.: 350,060

June 24, 2022
6:14 pm ET	INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Karuna Therapeutics, Inc. with Losses to Contact the Firm Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Karuna Therapeutics, Inc. ("Karuna" or "the Company")...(Newsfile)
June 18, 2022
2:30 pm ET	INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Karuna Therapeutics, Inc. with Losses to Contact the Firm LOS ANGELES, CA / ACCESSWIRE / June 18, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofKaruna Therapeutics, Inc. ("Karuna" or "the Company")...(Accesswire)
June 16, 2022
10:54 am ET	INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Karuna Therapeutics, Inc. with Losses to Contact the Firm The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Karuna Therapeutics, Inc. ("Karuna" or "the Company") (NASDAQ: KRTX) for violations of the securities laws. (BusinessWire)
June 06, 2022
6:30 am ET	Karuna Therapeutics to Present at Upcoming Investor Conferences Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will...(BusinessWire)
May 18, 2022
6:30 am ET	Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer's Disease Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a virtual...(BusinessWire)
May 05, 2022
6:30 am ET	Karuna Therapeutics Reports First Quarter 2022 Financial Results and Provides General Business Update --Topline data from the Phase 3 EMERGENT-2 and EMERGENT-3 trials expected in the third quarter of 2022 and in the first quarter of 2023, respectively --On track to initiate Phase 3 program evaluating KarXT for the treatment of psychosis in...(BusinessWire)
May 03, 2022
6:30 am ET	Karuna Therapeutics to Present at the 2022 RBC Capital Markets Global Healthcare Conference Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Andrew Miller, Ph.D...(BusinessWire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and